2022
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Mehra R, Flamand Y, Quon H, Garcia J, Weinstein G, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Gross N, Bell R, Saba N, Lango M, Bayon R, Burtness B, Ferris R. Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2022, 40: 6077-6077. DOI: 10.1200/jco.2022.40.16_suppl.6077.Peer-Reviewed Original ResearchProgression-free survivalOropharynx cancerOverall survivalSmoking statusTransoral surgeryAdjuvant treatmentPerformance statusPrimary siteECOG-ACRIN Cancer Research GroupFirst treatment approachHistory of smokingPhase II trialKaplan-Meier methodLog-rank testCancer Research GroupSignificant differencesWilcoxon rank sum testChi-square testRank sum testDefinitive chemoradiationEvaluable ptsOS ratesEfficacy outcomesExtranodal extensionII trial
2021
TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.
Bourhis J, Burtness B, Licitra L, Nutting C, Schoenfeld J, Sarkouh R, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen E. TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer. Journal Of Clinical Oncology 2021, 39: tps6091-tps6091. DOI: 10.1200/jco.2021.39.15_suppl.tps6091.Peer-Reviewed Original ResearchEvent-free survivalEFS eventsConcurrent chemoradiationAdvanced squamous cell carcinomaRandomized phase 2 studyECOG PS 0T cell-dependent pathwayLocoregional control ratePhase 2 studyPhase 3 trialPlatinum-based chemotherapySquamous cell carcinomaBiomarkers of responseStandard of careThree-year followIntensity-modulated radiotherapyExposure-response relationship× ULNBackbone therapyDefinitive chemoradiationEligible patientsLA-SCCHNMonotherapy periodX ULNConcurrent chemoradiotherapy
2017
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
Burtness B, Haddad R, Dinis J, Trigo Perez J, Yokota T, Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia C, Chaves-Conde M, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen E. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal Of Clinical Oncology 2017, 35: 6001-6001. DOI: 10.1200/jco.2017.35.15_suppl.6001.Peer-Reviewed Original ResearchDisease-free survivalPhase III trialsIII trialsEGFR inhibitionMedian disease-free survivalRecurrent/metastatic diseaseErbB family blocker afatinibPre-planned interim analysisECOG PS 0Median treatment durationSquamous cell cancerDefinitive chemoradiationECOG PSEligible ptsAdvanced HNSCCConcurrent cisplatinN2 diseasePrimary endpointAdjuvant therapyMetastatic diseasePS 0Complete responseDisease recurrenceMedian ageNodal stage
2016
Treatment de-intensification strategies for head and neck cancer
Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapyCombined Modality TherapyHead and Neck NeoplasmsHumansMinimally Invasive Surgical ProceduresOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomavirus InfectionsRadiotherapy DosageRadiotherapy, AdjuvantSquamous Cell Carcinoma of Head and NeckConceptsHigh-risk human papillomavirus infectionHuman papillomavirus infectionLong-term morbiditySquamous cell cancerSquamous cell carcinomaDe-intensification strategiesIntensive treatment regimensAltered fractionation schemesDefinitive chemoradiationAdjuvant radiationPapillomavirus infectionCell cancerImpairs qualityTreatment regimensCell carcinomaNeck cancerRecent trialsSimilar efficacySuch cancersInvasive surgeryTreatment intensityCancerRadiation dosePreliminary dataSurgery
2012
LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.
Burtness B, Bourhis J, Vermorken J, Dai L, Lind C, Ehrnrooth E, Cohen E. LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. Journal Of Clinical Oncology 2012, 30: tps5599-tps5599. DOI: 10.1200/jco.2012.30.15_suppl.tps5599.Peer-Reviewed Original ResearchDisease-free survivalNeck dissectionPO QDAdvanced squamous cell cancerIrreversible ErbB family blockerAdequate bone marrowErbB family blockerStudy of afatinibSubsequent neck dissectionCompletion of chemoradiationEvidence of diseaseHigh-risk patientsSecond primary tumorsHealth-related qualityBase of tongueSquamous cell cancerRisk of recurrenceNeck cancer patientsPlatinum-based chemoradiationSalivary gland cancerConcurrent cisplatinCurative intentDefinitive chemoradiationPrior therapyStudy medication